Alpha Healthcare Acquisition Corp.
AHAC
NASDAQ Global Select10.96
USD
+0.81
- -
Alpha Healthcare Acquisition Corp.
AHAC
(NASDAQ Global Select)
Recent
price
10.96
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Alpha Healthcare Acquisition Corp. (AHAC), a blank check company formed in 2020 and headquartered in New York, New York, focuses on effecting mergers, capital stock exchanges, asset acquisitions, stock purchases, reorganizations, or similar business combinations with one or more businesses, primarily targeting companies in the healthcare industry across services, therapeutics, devices, diagnostics, healthcare technology, and animal health in the United States. The company offers no current operational products or services beyond its special purpose acquisition structure, including units, Class A common stock, and warrants traded on Nasdaq prior to any de-SPAC transaction. In 2021, AHAC completed a business combination with Humacyte, Inc., a clinical-stage biotechnology company developing universally implantable bioengineered human tissues, resulting in AHAC's delisting and SEC registration revocation as it became part of the combined entity Humacyte (Nasdaq: HUMA). No significant operational activities, new product launches, funding rounds, or strategic shifts have occurred for AHAC independently since the merger, with recent market data reflecting legacy trading of units at approximately $10.96 as of late 2025.
Humacyte Announces Successful Closing of Business Combination with Alpha Healthcare Acquisition Corp.
Alpha Healthcare Acquisition Corp. Sets August 24, 2021, for Special Shareholder Meeting to Vote on Humacyte Business Combination
EXCLUSIVE: Humacyte, Alpha Healthcare CEOs Talk SPAC Deal, Technology, Trials On 'SPACs Attack'
2 SPAC Stocks That Could Be 10-Baggers
Humacyte to Present Long-Term Follow-Up Data from Phase 2 Vascular Access Trial at Charing Cross (CX) International Symposium 2021
Humacyte: Disrupting The Organ Transplant Industry
Regenerative Tissue Developer Humacyte Going Public Via SPAC